We’ve Been Testing Therapy Like It’s a Pill – and some Patients Are Paying the Price

Why It Matters

Because funding and guideline bodies prioritize RCT evidence, the over‑reliance on CBT restricts patient choice and perpetuates disparities in mental‑health outcomes, urging policymakers to adopt more inclusive evaluation methods.

Key Takeaways

• CBT dominates UK NHS and US mental health funding due to RCT suitability
• RCTs favor brief, measurable treatments, sidelining complex therapies
• BAME, learning‑difficulty, and complex‑need patients show poorer outcomes with CBT
• Observational NHS data is underused in NICE guidelines despite large sample size
• Diversifying research methods could broaden therapy choices and improve equity

Pulse Analysis

The rise of cognitive‑behavioural therapy in publicly funded systems is no accident; its structured, time‑limited protocol aligns neatly with the randomised controlled trial model that underpins most health‑technology assessments. Funding agencies and bodies such as NICE and the US National Institute for Mental Health reward interventions that can be packaged into a pill‑like format, funneling research dollars and service contracts toward CBT while marginalising modalities that resist standardisation. This alignment has created a feedback loop where CBT’s evidence base expands, reinforcing its status as the default offering across the NHS Talking Therapies programme and Medicare‑covered mental‑health services.

However, the very strengths of RCTs—tight control, short duration, and quantifiable endpoints—become weaknesses when applied to psychotherapy. Therapy often evolves over months, adapts to individual narratives, and targets outcomes like self‑understanding that defy simple symptom scales. Qualitative studies repeatedly show that patients seek deeper personal insight rather than merely reduced anxiety scores, a nuance lost when CBT is forced into narrow measurement frameworks. Consequently, the evidence hierarchy favours a narrow slice of therapeutic practice, leaving many effective approaches under‑researched and under‑funded.

The policy fallout is stark: patients from BAME backgrounds, those with learning difficulties, and individuals with complex mental‑health needs report lower response rates to CBT, yet guidelines continue to prioritise it. Leveraging the NHS’s massive routine outcomes dataset, alongside mixed‑methods research that captures lived experience, could rebalance the evidence landscape. By broadening evaluation tools beyond RCTs, health systems can expand the repertoire of endorsed therapies, improve equity, and ultimately deliver mental‑health care that reflects the diverse goals of the populations it serves.